Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.37 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29326138 | 0.91 | TRPV1 (0.44) | TRPV1HCRTR1VNN1HCRTR2 | |
| SCHEMBL27182175 | 0.91 | CRHR1 (0.40) | RORCROCK2CRHR1HCRTR1VNN1 | |
| SCHEMBL27182181 | 0.81 | NLRP3 (0.45) | HCRTR1VNN1HCRTR2 | |
| SCHEMBL29326158 | 0.80 | IL1B (0.41) | TRPV1HCRTR1HCRTR2 | |
| SCHEMBL30837966 | 0.78 | TRPV1 (0.48) | TRPV1HCRTR1VNN1HCRTR2 | |
| SCHEMBL29326142 | 0.78 | IL1B (0.44) | — | |
| SCHEMBL27182190 | 0.75 | CRHR1 (0.44) | CRHR1 | |
| SCHEMBL29326010 | 0.75 | ALDH1A1 (0.41) | TRPV1 | |
| SCHEMBL29131855 | 0.75 | IL1B (0.43) | TRPV1HCRTR1VNN1HCRTR2 | |
| SCHEMBL29131858 | 0.75 | IL1B (0.43) | TRPV1HCRTR1VNN1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | TRPV1 68/4885RORC 315/4885JAK2 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.